Ionizable lipid nanoparticles (LNPs) are the most clinically advanced nano‐delivery system
for therapeutic nucleic acids. The great effort put in the development of ionizable lipids with …

Many emerging therapies rely on the delivery of biological cargo into the cytosol.
Nanoparticle delivery systems hold great potential to deliver these therapeutics but are …

Lipid nanoparticles (LNPs) have recently emerged as a powerful and versatile clinically
approved platform for nucleic acid delivery, specifically for mRNA vaccines. A major …

Protein-based therapeutics are an attractive alternative to established therapeutic
approaches and represent one of the fastest growing families of drugs. While many of these …

Rational design of multifunctional nanomedicines has revolutionized the therapeutic efficacy
of cancers. Herein, we have constructed the functional nucleic acids (FNAs)-engineered …

Oligonucleotides (ONs) comprise a rapidly growing class of therapeutics. In recent years, the
list of FDA-approved ON therapies has rapidly expanded. ONs are small (15–30 bp) …

Drug delivery systems (DDS) triggered by local microenvironment represents the state-of-art
of nanomedicine design, where the triggering hallmarks at intracellular and subcellular …

The complexity of nanoscale interactions between biomaterials and cells has limited the
realization of the ultimate vision of nanotechnology in diagnostics and therapeutics. As such …

Nanoparticles have been widely applied as gene carrier for improving RNA interference
(RNAi) efficiency in medical and agricultural fields. However, the mechanism and delivery …

Polyethlyenimine (PEI) was introduced 1995 as a cationic polymer for nucleic acid delivery.
PEI and its derivatives are extensively used in basic research and as reference formulations …